Cantitate/Preț
Produs

Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance: Resistance to Targeted Anti-Cancer Therapeutics, cartea 2

Editat de Benjamin Bonavida
en Limba Engleză Hardback – 5 aug 2013
​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 109004 lei  6-8 săpt.
  Springer – 22 aug 2015 109004 lei  6-8 săpt.
Hardback (1) 109388 lei  6-8 săpt.
  Springer – 5 aug 2013 109388 lei  6-8 săpt.

Din seria Resistance to Targeted Anti-Cancer Therapeutics

Preț: 109388 lei

Preț vechi: 115145 lei
-5% Nou

Puncte Express: 1641

Preț estimativ în valută:
20935 21690$ 17471£

Carte tipărită la comandă

Livrare economică 22 martie-05 aprilie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781461476535
ISBN-10: 1461476534
Pagini: 255
Ilustrații: XIII, 202 p.
Dimensiuni: 155 x 235 x 17 mm
Greutate: 0.41 kg
Ediția:2013
Editura: Springer
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:New York, NY, United States

Public țintă

Research

Cuprins

Preface.- Introduction and generation of chimeric and humanized mAbs.- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment.- Antibodies directed against different major cancers: Effects when used  alone or in combination with drugs.- Mechanisms of antibodies-mediated responses, in vitro and in vivo.- Molecular Pathways.- Molecular Signatures.- Identification of resistance targets for intervention.- Various chemicals that can sensitize resistant tumor cells.- Other mAbs.- Proteasome inhibitors.- Divalent mAbs.- Antibodies coupled to chemical inhibitors.- Antibodies coupled to cytokines.- Nanoparticles with mAbs.- Index.

Notă biografică

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

Textul de pe ultima copertă

The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance.
Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.

Caracteristici

Summarizes common and unique features of mAbs against various cancers Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs Covers the potential use of the combination treatment of mAbs with other drugs/mAbs to reverse resistance Includes supplementary material: sn.pub/extras